FP&A And Runway Management

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with FP&A And Runway Management in the context of Biotechnology. Leadership across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators sought an integrated cash and P&L planning framework, scenario modeling, and rolling forecasts aligned to program milestones and business development (BD) events to extend runway and optimize burn. The diagnostic surfaced specific pain points and control gaps:

• Fragmented planning and opaque cash runway. Cash, P&L, and headcount plans were built in disconnected spreadsheets. The organization could not tie cash runway to development and regulatory milestones, gating decisions, or potential BD transactions (partnerships, options, royalty monetizations).
• Inadequate driver-based models. Clinical trial expenses were budgeted top-down rather than using operational drivers (sites, enrollment curves, visit schedules, screen failure and discontinuation rates, pass-throughs). CMC and external manufacturing costs were not modeled from batch campaigns, yields, batch sizes, and CDMO SOW milestones; commercial GTN and working capital were treated as simple percentages.
• Weak scenario planning and sensitivity analysis. Scenarios (base/accelerated/downside) did not capture key uncertainties (enrollment slippage, protocol amendments, CMC yield loss, CDMO delays, pricing/GTN erosion, FX, inflation). Contingency levers (scope deferrals, vendor rephasing, headcount ramps, tranche financing) were not codified.
• Rolling forecast and S&OP misalignment. Monthly/quarterly rolling forecasts were not linked to clinical operations, CMC campaign plans, or S&OP for commercial supply. Forecasts lagged actuals; change-control discipline was limited.
• Vendor and SOW governance gaps. CRO/CDMO/consulting SOWs proliferated without standardized milestones or burn visibility; prepayments, pass-throughs, change orders, and currency exposures were not tracked consistently; legal terms (termination rights, step-down options) were under-leveraged.
• Commercial readiness and GTN under-modeled. For late-stage and commercial assets, gross-to-net (GTN) waterfalls lacked detail for payer mix, 340B capture, Medicaid Best Price, Part D redesign and inflation rebates, copay/bridge program impacts, and SP/SD data lags; revenue recognition and working capital requirements were not synchronized with launch plans.
• Capital plan and BD pipeline not integrated. Financing options (equity tranches, venture debt, R&D credits, grants, royalty monetization, PRVs) were evaluated in isolation from operating plans and valuation effects; board materials lacked a clear “cash-in, cash-out, value inflection” bridge.
• Close and forecast process immaturity. Month-end close took 10–15 business days; accrual policies for CRO/CDMO pass-throughs were inconsistent; ERP (e.g., NetSuite/SAP) and planning tools (Adaptive/Anaplan/Excel) were not integrated; data lineage and audit trails were incomplete.
• Headcount and vendor mix not tied to milestones. Hiring plans did not reflect gating decisions; contractor/consultant spend was reactive; spans and layers drifted; resource conflicts surfaced near IND/IMPD and pivotal trial starts.
• Unclear ROI and runway extension narrative. Leadership and investors lacked a defensible view linking cost optimization and sequencing to extended runway, optionality for BD, and probability-adjusted value creation.

Indicative KPIs and signals included: runway variance vs. board guidance >2 quarters; forecast error >15% on CRO/CDMO invoices; frequent SOW change orders and pass-through spikes; enrollment and site start-up slippage unreflected in budgets; CMC campaign rework not rephased; GTN actuals missing payer/340B dynamics; headcount overruns; close cycle exceeding 8 business days; and insufficient sensitivity to FX and inflation in multi-regional programs.

2) Project Objective

The primary objective focused on building and activating an integrated FP&A and runway management system—driver-based cash/P&L models, rolling forecasts, and milestone- and BD-aligned scenarios—that extended runway, optimized burn, and improved decision velocity for biotech executives and boards.

Secondary objectives included:

• Developing driver-based clinical, CMC/Tech Ops, and commercial financial models tied to operational plans (enrollment curves, site activations, batch campaigns, yield and scrap, GTN/working capital).
• Standing up rolling forecasts (monthly/quarterly) with clear change-control, variance analysis, and linkages to S&OP and program governance.
• Codifying scenario planning (base/upside/downside) with sensitivity analyses and pre-approved levers (scope, vendor rephasing, hiring, tranches) to preserve optionality.
• Instituting vendor/SOW governance: milestone and deliverable tracking, pass-through management, FX/hedging posture, and risk-adjusted accruals.
• Integrating commercialization economics where relevant: detailed GTN waterfall, SP/SD and HUB implications, Part D redesign and inflation rebates, 340B ceiling prices, payer mix, working capital, and launch investment pacing.
• Aligning capital strategy and BD events (partnerships, royalties, venture debt, grants) with operating scenarios; preparing board-ready investment cases.
• Upgrading planning architecture: ERP/HRIS/project systems connected to planning (Anaplan/Adaptive/Excel model with data governance, lineage, and SOX-lite controls as appropriate).
• Embedding KPI dashboards for executives and functional owners; creating a repeatable CFO “runway and value inflection” narrative for investor updates.

3) Methodology and Approach

Workstream 1: CFO Operating Model and Planning Principles

We established the FP&A operating cadence, roles, and planning guardrails.

• Defined planning horizons (13–18 month rolling forecast; 24–36 month strategic model), cadence (monthly/quarterly), and ownership (FP&A vs. functional leaders).
• Set change-control and variance taxonomy (mix, price, volume, timing, FX, scope); established gating with Program Governance for material plan changes.
• Aligned capitalization policy, accrual rules (CRO/CDMO pass-throughs), and revenue recognition with accounting policy and audit readiness.

This created the foundation for a discipline-based planning culture and shortened decision cycles.

Workstream 2: Driver-Based Clinical Model

We built a bottom-up clinical model tied to trial operational drivers.

• Enrollment engine: country/site startup curves, screen failure and dropout rates, visit schedules, and per-visit costs; monitored impacts of protocol amendments, DSMB reviews, and rescue strategies.
• Cost structure: base FTE mix, CRO unit rates, monitoring frequency (SDV vs. RBM), central labs, imaging, eCOA/ePRO, DSMB/IRB fees, patient travel, decentralized/hybrid cost differentials, and pass-throughs.
• Scenario toggles: site count changes, enrollment acceleration/deceleration, competitive trials, country adds/drops, regulatory delays, and currency exposures.
• Outputs: monthly cash and accrual views, milestone-based outlays, enrollment and LSLV/DBL timing, and variance drivers.

The model enabled “what-if” analyses with clinical leadership and allowed quick rephasing based on site performance.

Workstream 3: CMC/Tech Ops and External Manufacturing Model

We constructed a campaign-based CMC model grounded in process and supply realities.

• Campaign planning: DS/DP batch plans, batch sizes and yields, failure/scrap assumptions, resin/filter/cassette lifetime, release testing, stability, and serialization/pack/label timelines.
• CDMO SOWs: milestone payments, tech transfer costs, engineering runs, PPQ, and lot release; added buffers for E&L/CCI, method robustness, and Annex 1 compliance for sterile products.
• Materials and logistics: raw materials lead times, supplier MOQs, dual-source premiums, cold chain (2–8°C, frozen, cryogenic), and returns/disposal costs.
• Scenario toggles: capacity constraints, yield loss, change controls, rework, and regulatory addenda; FX and inflation impacts for ex-US CDMOs.
• Outputs: cash and accrual curves, inventory and working capital, cost per lot, and risk-adjusted campaign economics.

This delivered a realistic view of manufacturing burn and readiness tied to clinical and launch plans.

Workstream 4: Commercialization, GTN, and Working Capital Model (if applicable)

We modeled launch and commercial dynamics with a defensible GTN and cash conversion cycle.

• Demand and uptake: patient flow model (diagnosis → eligibility → initiation), HCP/IDN adoption curves, payer and channel mix, SP/SD and buy-and-bill shares.
• GTN waterfall: rebates, chargebacks, 340B capture, Medicaid Best Price and URA, Part D redesign and inflation rebates, copay/bridge programs, returns, distribution/admin fees, and wholesaler inventory dynamics.
• Working capital: DSO/DSO assumptions by channel, inventory days, and AP terms; launch investment pacing (field, HUB, SP, distribution, medical, MLR content).
• Scenario toggles: payer access timing, copay accumulator impact, IRA effects, competitor launches, and tender exposure ex-US.
• Outputs: monthly revenue, net cash, GTN % by payer/channel, and operating cash impacts.

This brought commercial realism to cash runway and linked access and pull-through levers to financial outcomes.

Workstream 5: Headcount, Vendor Mix, and Opex Model

We aligned hiring and vendor spend to milestones and capacity needs.

• Headcount ramps: spans/layers targets, hiring timing by function, and contractor-to-FTE conversions; included recruiting lead times and onboarding costs.
• Vendor mix: CRO/CDMO/consulting/vendor rosters with SOW milestones; pass-through governance; KPI-linked payment triggers; FX/hedging policy where relevant.
• Scenario toggles: hiring freeze/deferral levers, vendor rephasing, insource/outsource trade-offs, and facility costs.
• Outputs: cash and P&L impact by function and vendor; productivity and ramp readiness signals.

This provided a transparent path to align people and partners with program gates and preserve optionality.

Workstream 6: Capital Plan, BD Events, and Runway Extension Levers

We integrated financing, partnering, and non-dilutive options into the planning spine.

• Capital menu: equity tranches, venture debt, term loans, working capital lines, R&D tax credits, grants, PRVs, royalty monetizations, and ex-US partnerships with milestones; modeled covenants, interest, and dilution.
• BD pipeline: partnership scenarios (co-dev, out-licensing, regional) with deal contours; probability-adjusted timing; operational implications.
• Runway levers: scope deferrals (non-core programs), CMC campaign rephasing, clinical protocol optimizations, vendor renegotiations, and headcount timing; impact on value inflections.
• Outputs: cash runway by scenario, value inflection map, and board-ready decision packages.

This created a proactive capital strategy aligned to scientific and commercial milestones.

Workstream 7: Rolling Forecast, S&OP Integration, and Variance Management

We operationalized monthly/quarterly rolling forecasts linked to cross-functional cadences.

• Rolling forecast process: monthly updates on enrollment, site starts, CDMO campaigns, and GTN/access signals feeding an FP&A refresh; quarterly rebaseline; strict change-control with narrative variance.
• Integration: S&OP connection for supply plans and launch staging; program governance to synchronize plan changes; cadence with CMC and Clinical for key risks and decisions.
• Variance dashboards: visualized drivers by function; forecast accuracy tracking and accountability; automated management packs.

This improved forecast accuracy and created an early-warning system for runway risks.

Workstream 8: Systems, Data Architecture, and Close Acceleration

We put in place a pragmatic toolchain with audit-ready data lineage.

• Architecture: ERP (NetSuite/SAP) integrated with AP, purchasing, and project codes; HRIS and T&E feeds; project trackers (CTMS, eTMF, CDMO trackers) connected to planning (Adaptive/Anaplan or controlled Excel models).
• Close optimization: standardized accruals for CRO/CDMO; automated feeds; reduced close cycle to targeted business days; segregation of duties and access controls.
• Data governance: data dictionary, lineage, and quality checks; model version control; board-quality reporting templates.

This gave the CFO a single source of truth for board and investor communications.

Workstream 9: Cost Optimization and Vendor/SOW Governance

We targeted non-dilutive runway extension without undermining science or compliance.

• Category strategies: CRO rate cards and FTE mix, CDMO batch economies, lab consumables and logistics, software licenses, facilities, and professional services.
• SOW hygiene: milestones tied to deliverables; change-order discipline; pass-through scrutiny; payment terms aligned to cash profile; FX and inflation clauses.
• Negotiation playbooks: benchmarks, should-costs, fallback positions; decision rights for approvals; risk/benefit framework for dual-sourcing and buffers.

This created structured levers to reduce burn while preserving execution quality.

Workstream 10: Executive/Board Reporting and Investor Narrative

We converted analytics into clear decision materials and disclosures.

• Runway dashboard: cash by month/quarter, burn rate, scenario bands, and required capital timing.
• Value inflection map: milestone timing (preclinical, IND/IMPD, FIH, POC, pivotal, filing/approval, launch) vs. costs and capital plan.
• BD and capital exhibits: option values and contingencies; dilution/covenant impacts; “uses of proceeds” linked to milestones.
• Risk register: top 10 operational/financial risks with triggers and mitigations.

This enabled fast, informed board decisions and credible investor guidance.

4) Data Request

We requested detailed data to execute FP&A And Runway Management across the therapeutics spectrum. Typical horizons: 24–36 months for strategic planning; 13–18 months rolling forecast; monthly granularity, with weekly operational feeds where feasible.

• Clinical operations:
  • Trial calendars (FPI, LSLV, DBL), country/site lists, startup timelines, enrollment curves, visit schedules, monitoring plans, pass-through assumptions, CRO rate cards, SOWs/change orders, and invoice histories.
• CMC/Tech Ops:
  • Campaign plans (DS/DP), yields, batch sizes, QC/QA release and stability, CDMO SOW milestones, materials BOM and lead times, logistics (cold chain), inventory policies, and invoice histories.
• Commercial (if applicable):
  • Demand build assumptions, payer mix, SP/SD routing, buy-and-bill share, GTN elements (rebates, chargebacks, 340B, Best Price/URA, Part D redesign/inflation rebates), returns, distribution fees, and working-capital policies.
• Corporate/overheads:
  • Headcount roster with start dates/comp/benefits, contractor/vendor lists, facility and IT costs, professional services, and insurance.
• Capital and BD:
  • Cap table, debt covenants, funding timelines, grant/credit programs, BD pipeline with terms/milestones, royalty/PRV options, and prior transaction summaries.
• Finance systems and policies:
  • ERP chart of accounts, project codes, AP/PO data, HRIS feeds, accrual policies (CRO/CDMO, GTN), close calendar, prior board packs, and audit findings (if any).
• Treasury and FX:
  • Bank accounts, investment policy, currency exposures (CRO/CDMO invoices), and hedging posture.

Common data pitfalls included inconsistent project coding across functions, CRO/CDMO invoice lags and pass-through lumping, incomplete site/enrollment trackers, CDMO milestone changes not reflected in forecast, sparse GTN data lineage, working capital blind spots, and manual spreadsheet calculations without version control. We implemented a data dictionary and reconciliation routines before financial modeling.

5) Questions for Client

• What runway target (months/quarters) must be achieved under base and downside scenarios, and what value inflections should precede the next capital raise?
• Which programs are strategic vs. optional in the next 12–24 months, and what gating criteria will drive defer/accelerate decisions?
• How should risks be parameterized (enrollment slippage, CMC yield loss, GTN erosion, FX/inflation), and what sensitivity bands are acceptable for board reporting?
• What levers are in-bounds for runway extension (vendor rephasing, headcount timing, scope deferral), and what constraints (quality, regulatory) are non-negotiable?
• What BD and capital options are credible in the next 12 months (partnerships, royalties, grants, debt), and how should they be sequenced relative to milestones?
• What planning tool posture is preferred (Adaptive/Anaplan vs. governed Excel) given timeline and budget; what integrations with ERP/HRIS/CTMS/CDMO trackers are feasible?
• Which GTN elements require deeper modeling for late-stage/commercial assets (340B, Best Price/URA, Part D redesign/inflation rebates, SP/SD dynamics)?
• What close-cycle target and accrual policy changes are acceptable to improve forecast accuracy and audit readiness?
• What executive/board dashboard cadence, content, and thresholds should govern escalation and scenario activation?
• How should we align incentives and OKRs for functions (Clinical, CMC, Access, Commercial) to the rolling forecast and runway goals?

6) Interview Guide for Subject Matter Experts

Chief Financial Officer / Head of FP&A

• What are the current runway and forecast accuracy issues; where do forecasts diverge from actuals?
• Which board KPIs and scenario narratives resonate; what documentation gaps exist for decisions?
• Where are data lineage and close-cycle bottlenecks?

Head of Clinical Operations / Program Directors

• What enrollment and site-start assumptions drive current plans; where are risks most acute?
• How do protocol amendments or decentralization affect costs and timelines?
• Which CRO levers (site mix, monitoring) are available if slippage occurs?

Head of CMC / Tech Ops / External Manufacturing

• What are the next 12–18 months of campaigns; where are yield or capacity risks?
• Which CDMO SOW milestones and change orders are pending; what buffers are prudent?
• How do materials lead times and cold-chain constraints affect cash timing?

Head of Market Access / Commercial (if applicable)

• What payer access steps and GTN elements need deeper modeling; where is SP/SD routing changing?
• How will Part D redesign and inflation rebates affect net revenue and cash?
• What working-capital assumptions (inventory, AR) are realistic at launch?

Head of BD / Corporate Development

• What BD options are likely in the planning window; what milestones and economics define a credible deal?
• How should we value royalty/partner options vs. dilution and operational trade-offs?

Head of HR / Talent

• Where are critical hires vs. deferrable roles; what are recruiting lead times?
• How will spans/layers and contractor mix change under different scenarios?

Legal / Procurement / Contracts

• What SOW and contract terms (termination, payment schedules, FX) enable cash management?
• Where do change orders proliferate; how can we standardize milestones?

IT / Systems / Controller

• What ERP/HRIS/CTMS/CDMO integration is feasible; where can we automate accruals and feeds?
• What controls and audit trails are required; how can we shorten close?

Treasury / Investor Relations

• What is the investment policy and cash ladder; where are FX exposures?
• How should we frame the runway and value inflection narrative to investors?

7) Timeline

We executed a 12–14 week plan tailored to FP&A And Runway Management within Finance.

• Weeks 1–2: Mobilize, Diagnostic, and Planning Principles
  • Conducted executive and functional interviews; collected financials, SOWs, clinical/CMC plans, and GTN inputs; documented current forecast/close processes.
  • Defined planning horizons, variance taxonomy, and governance; agreed modeling tool posture and data pipeline scope.
  • Decision Gate A: Approved planning principles, governance, and data remediation plan.
• Weeks 3–4: Driver Models—Clinical and CMC
  • Built enrollment and site-driven clinical model; constructed campaign-based CMC model; linked to monthly cash/accrual outputs; validated with functional owners.
  • Decision Gate B: Ratified model structures and base assumptions; aligned variance drivers and sensitivity ranges.
• Weeks 5–6: Commercial/GTN (if applicable) and Opex/Headcount
  • Developed GTN waterfall, working capital, and launch investment model; built headcount/vendor opex model; aligned with S&OP/launch plans.
  • Decision Gate C: Approved commercial and opex models; set GTN and working-capital assumptions for scenarios.
• Weeks 7–8: Scenarios, Runway Levers, and Capital Plan Integration
  • Constructed base/upside/downside scenarios; quantified runway extension levers; integrated BD/capital events (royalties, debt, equity, grants) and valuation impacts.
  • Decision Gate D: Endorsed scenarios, levers, and capital options; prioritized board decision packages.
• Weeks 9–10: Rolling Forecast, Variance Dashboards, and S&OP Integration
  • Launched monthly/quarterly rolling forecast cadence with variance analysis; integrated with program governance and S&OP; deployed dashboards.
  • Decision Gate E: Confirmed forecast process and dashboard integrity; agreed escalation thresholds.
• Weeks 11–12: Systems/Data Integration and Close Acceleration
  • Connected ERP/HRIS/CTMS/CDMO trackers to planning; standardized accruals; shortened close; implemented data governance and controls; documented lineage.
  • Decision Gate F: Validated close-cycle target and data integrity; locked board reporting templates.
• Weeks 13–14: Board Materials and Handoff
  • Delivered investment cases and runway narratives; trained FP&A and functional leads; formalized quarterly scenario refresh and change-control processes.

Critical path items included CRO/CDMO data availability, SOW milestone clarity, GTN data granularity for late-stage programs, ERP integration bandwidth, and governance alignment for scenario activation.

8) Deliverables

• Integrated Driver-Based Financial Model
  • Clinical enrollment/site model; CMC campaign model; opex/headcount; commercial GTN/working capital (if applicable); cash and P&L outputs with sensitivities.
• Scenario and Runway Planner
  • Base/upside/downside scenarios with value inflection timelines; runway extension levers; capital/BD options; Excel/Adaptive/Anaplan artifact with user guide.
• Rolling Forecast and Variance Dashboard
  • Monthly/quarterly forecast process, variance taxonomy, and dashboards by function; accuracy tracking and escalation triggers.
• Vendor/SOW Governance Toolkit
  • SOW and milestone templates, pass-through policies, change-order and approval flow, rate card benchmarks, FX/inflation clauses, and negotiation playbooks.
• Commercial GTN and Working Capital Pack (if applicable)
  • GTN waterfall model and documentation; payer/channel mix assumptions; Part D redesign and inflation rebate modules; 340B/Best Price considerations; working-capital model.
• Close Acceleration and Data Governance SOPs
  • Accrual standards for CRO/CDMO and GTN; ERP integration specs; data dictionary and lineage; model version control; SOX-lite controls and audit readiness.
• Capital Strategy and BD Option Cases
  • Royalty monetization, venture debt, grants, equity tranches; dilution/covenant impacts; sequencing recommendations aligned to milestones.
• Executive/Board Reporting Suite
  • Runway dashboard, value inflection map, scenario exhibits, risk register, and decision memos; investor-ready “uses of proceeds” narratives.
• Operating Calendar and Governance Charter
  • Rolling forecast cadence, S&OP integration, Program Governance gates, and data refresh schedule; roles and decision rights.
• Training and Handoff Materials
  • FP&A playbook; how-to guides for model updates; dashboard user guides; change-control checklist; RACI for forecasts and accruals.

9) Industry Insights

Market and policy dynamics directly inform FP&A And Runway Management within Biotechnology and Finance.

• Capital markets volatility raises the bar for planning:
  • Longer fundraising cycles and higher cost of capital require clearer “cash-in, cash-out, value inflection” narratives supported by driver-based models. Boards expect scenario-ready plans with pre-defined levers, not static budgets.
• Clinical and CMC execution risks dominate burn:
  • Enrollment variability, protocol amendments, and site performance can swing burn by double digits; campaign yields, change controls, and CDMO capacity can shift cash curves materially. Modeling from operational drivers is essential.
• Commercial GTN complexity affects cash more than revenue:
  • 340B capture, Medicaid Best Price/URA, Part D redesign and inflation rebates, copay programs, and SP/SD routing materially affect net cash. GTN waterfalls and working-capital models should be board-level artifacts for late-stage companies.
• IRA and policy shifts create new accrual requirements:
  • Inflation-based rebates and manufacturer liabilities in Part D must be forecast and accrued; selection and negotiation risks require scenario treatment. FP&A models should parameterize these flows early.
• Vendor governance is a runway lever:
  • Standardized SOWs, milestone-based payments, pass-through scrutiny, and FX/inflation clauses improve predictability and reduce leakage without impairing quality or timelines. CRO/CDMO relationships benefit from transparency and shared KPIs.
• Rolling forecasts and S&OP integration win over annual budgets:
  • Monthly/quarterly reforecasts linked to program governance and S&OP enable timely rephasing and defendable guidance. Executive teams increasingly replace static annual budgets with rolling, driver-based plans.
• Pragmatic tooling beats big-bang transformations:
  • Governed Excel or lightweight planning tools (Adaptive/Anaplan) with ERP/HRIS/CTMS feeds can deliver 80–90% of the value quickly. Data lineage, accrual standards, and variance discipline matter more than tool branding.
• What “good” looks like:
  • An integrated driver-based model across clinical, CMC, opex, and GTN; rolling forecasts and variance dashboards; scenario planning with pre-approved levers; vendor/SOW governance; close-cycle and data lineage improvements; and a capital/BD plan synchronized to milestones with investor-quality materials.
• Near-term watch points:
  • CDMO and CRO capacity constraints, FX/inflation impacts on international vendors, changing payer policies (340B, Part D redesign), and supply-chain shocks. Regular scenario refresh and S&OP integration mitigate surprises.

Implications for clients we served included enabling Emerging Therapeutic Biotech to build a right-sized, milestone-aligned planning system before first-in-human; supporting Clinical-Stage Biotech to rephase clinical and CMC burn and extend runway through vendor governance and scenario levers; equipping Commercial Biotech to model GTN and working capital credibly and synchronize launch investments to access and demand; guiding Platform Biotech to standardize FP&A toolkits and governance across programs; and providing Biotech Investors & Incubators with diligence frameworks to assess runway credibility, scenario preparedness, and capital efficiency across portfolio companies.